An Insight to the Toxic Effect of Sulfamerazine on Porcine Pancreatic Amylase and Lactate Dehydrogenase Activity: An In Vitro Study

Author(s): Avirup Malla, Koel Mukherjee, Mukulika Mandal, Aishwarya Mukherjee, Runa Sur, Suvroma Gupta*

Journal Name: Current Chemical Biology

Volume 15 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Sulfamerazine, a sulfonamide, has been routinely used to treat various bacterial infections, namely Pneumonia, Urinary tract infections, Shigellosis, Bronchitis, Prostatitis, and many more. It interferes with the bacterial folic acid biosynthesis, albeit higher eukaryotes are not susceptible to its action due to the inherent absence of this specific pathway.

Objective: In spite of its constant use, Sulfamerazine administration evokes serious issues like the development of antibacterial resistance through environmental contamination, although how it affects the eukaryotic system, specifically its target identification, has not been addressed in detail.

Methods: The source of the cell line, including when and from where it was obtained. Whether the cell line has recently been authenticated and by what method. Whether the cell line has recently been tested for mycoplasma contamination. Hela Cells are cultured as per the standard method, amylase and lactate dehydrogenase assay are conducted using a standard procedure with a spectrophotometer. Binding thermodynamics and conformational study have been estimated with isothermal titration calorimetry as well as with docking.

Results: Experimental observations reveal that Sulfamerazine inhibits porcine pancreatic amylase in a noncompetitive mode (IC50 of 0.96 mM). The binding of the drug to porcine pancreatic amylase is entropy-driven with conformational changes of the protein as indicated by concomitant redshift. It enhances the inhibitory effects of acarbose and cetapin on their in vitro pancreatic amylase activity. It augments lipid peroxidation and promotes lactic acidosis in a dose-dependent manner. Docking studies ensure effective interactions between Sulfamerazine and proteins like lactic dehydrogenase and porcine pancreatic amylase.

Conclusion: Detailed study is to be conducted to confirm whether the molecular scaffold of Sulfamerazine might serve as an effective repurposed drug acting as a lead molecule to design antidiabetic drugs of future use. Alternatively, it should be prescribed with caution under specific medical situations like diabetes, cancer and hepatic disorders manifesting lactic acidosis to avoid the crisis.

Keywords: Enzyme, lactic acidosis, diabetes, lipid peroxidation, non-competitive, docking.

[1]
Martin-Laurent F, Topp E, Billet L, et al. Environmental risk assessment of antibiotics in agroecosystems: ecotoxicological effects on aquatic microbial communities and dissemination of antimicrobial resistances and antibiotic biodegradation potential along the soil-water continuum. Environ Sci Pollut Res Int 2019; 26(18): 18930-7.
[http://dx.doi.org/10.1007/s11356-019-05122-0] [PMID: 31055743]
[2]
Ou D, Chen B, Bai R, Song P, Lin H. Contamination of sulfonamide antibiotics and sulfamethazine-resistant bacteria in the downstream and estuarine areas of Jiulong River in Southeast China. Environ Sci Pollut Res Int 2015; 22(16): 12104-13.
[http://dx.doi.org/10.1007/s11356-015-4473-z] [PMID: 25877900]
[3]
Baran W, Adamek E, Ziemiańska J, Sobczak A. Effects of the presence of sulfonamides in the environment and their influence on human health. J Hazard Mater 2011; 196: 1-15.
[http://dx.doi.org/10.1016/j.jhazmat.2011.08.082] [PMID: 21955662]
[4]
Petri WA. Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections Goodmans and Gilman’s the pharmacological basis of therapeutics (12th ed) New York: The MaGraw-Hill Companies Inc. 2011; pp. 1463-76.
[5]
Göçer H, Akıncıoğlu A, Öztaşkın N, Göksu S, Gülçin İ. Synthesis, antioxidant, and antiacetylcholinesterase activities of sulfonamide derivatives of dopamine-related compounds. Arch Pharm (Weinheim) 2013; 346(11): 783-92.
[http://dx.doi.org/10.1002/ardp.201300228] [PMID: 24591156]
[6]
Loubatieres A. The mechanism of action of the hypoglycemic sulfonamides; a concept based on investigations in animals and in man. Diabetes 1957; 6(5): 408-17.
[http://dx.doi.org/10.2337/diab.6.5.408] [PMID: 13461757]
[7]
Kajinuma H, Kuzuya TT, Ide T. Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs. Diabetes 1974; 23(5): 412-7.
[http://dx.doi.org/10.2337/diab.23.5.412] [PMID: 4208464]
[8]
Lebovitz HE, Feinglos MN. Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1978; 1(3): 189-98.
[http://dx.doi.org/10.2337/diacare.1.3.189] [PMID: 365478]
[9]
Luft D, Schmülling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978; 14(2): 75-87.
[http://dx.doi.org/10.1007/BF01263444] [PMID: 344119]
[10]
Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal Chem 1959; 31(3): 426-8.
[http://dx.doi.org/10.1021/ac60147a030]
[11]
Panda D, Rathinasamy K, Santra MK, Wilson L. Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc Natl Acad Sci USA 2005; 102(28): 9878-83.
[http://dx.doi.org/10.1073/pnas.0501821102] [PMID: 15985553]
[12]
Burlingham BT, Widlanski TS. An intuitive look at the relationship of Ki and IC50: amore general use for the Dixon plot. J Chem Educ 2003; 80(2): 214.
[http://dx.doi.org/10.1021/ed080p214]
[13]
Yoon SH, Robyt JF. Study of the inhibition of four alpha amylases by acarbose and its 4IV-alpha-maltohexaosyl and 4IV-alpha- maltododecaosyl analogues. Carbohydr Res 2003; 338(19): 1969-80.
[http://dx.doi.org/10.1016/S0008-6215(03)00293-3] [PMID: 14499573]
[14]
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha‐glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (2): CD003639.
[http://dx.doi.org/10.1002/14651858.CD003639.pub]
[15]
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-8.
[http://dx.doi.org/10.1016/0003-2697(79)90738-3] [PMID: 36810]
[16]
Yannis K. Purification and characterisation of lactate dehydrogenase: an undergraduate biochemistry laboratory experiment. Adv Biochem 2014; 2: 14-23.
[http://dx.doi.org/10.11648/j.ab.20140201.13]
[17]
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31(2): 455-61.
[PMID: 19499576]
[18]
Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 2006; 34(2): W116-8.
[http://dx.doi.org/10.1093/nar/gkl282]
[19]
Maity S, Mukherjee K, Banerjee A, Mukherjee S, Dasgupta D, Gupta S. Inhibition of porcine pancreatic amylase activity by sulfamethoxazole: structural and functional aspect. Protein J 2016; 35(3): 237-46.
[http://dx.doi.org/10.1007/s10930-016-9668-8]
[20]
Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 2005; 338(1): 668-76.
[http://dx.doi.org/10.1016/j.bbrc.2005.08.072] [PMID: 16126168]
[21]
Arora R, Vig AP, Arora S. Lipid peroxidation: a possible marker for diabetes. J Diabetes Metab S 2013; 11: 1-6.
[22]
Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014; 2014: 360438.
[http://dx.doi.org/10.1155/2014/360438] [PMID: 24999379]
[23]
Heaf J. Metformin in chronic kidney disease: time for a rethink. Perit Dial Int 2014; 34(4): 353-7.
[http://dx.doi.org/10.3747/pdi.2013.00344] [PMID: 24711640]
[24]
Ohnishi S, Mizutani H, Kawanishi S. The enhancement of oxidative DNA damage by anti-diabetic metformin, buformin, and phenformin, via nitrogen-centered radicals. Free Radic Res 2016; 50(8): 929-37.
[http://dx.doi.org/10.1080/10715762.2016.1204651] [PMID: 27328723]
[25]
Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995; 8(2): 127-34.
[http://dx.doi.org/10.1093/protein/8.2.127] [PMID: 7630882]
[26]
Roy D, Mukherjee K. Homology modeling and docking studies of human chitotriosidase with its natural inhibitors. J Proteins & Proteomics 2015; 6(2)
[27]
Warburg O. On the origin of cancer cells. Science 1956; 123(3191): 309-14.
[http://dx.doi.org/10.1126/science.123.3191.309] [PMID: 13298683]
[28]
Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004; 27(7): 1791-3.
[http://dx.doi.org/10.2337/diacare.27.7.1791] [PMID: 15220268]
[29]
Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S. Lactic dehydrogenase and cancer: an overview. Front Biosci 2015; 20: 1234-49.
[http://dx.doi.org/10.2741/4368] [PMID: 25961554]
[30]
Granchi C, Calvaresi EC, Tuccinardi T, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem 2013; 11(38): 6588-96.
[http://dx.doi.org/10.1039/c3ob40870a] [PMID: 23986182]
[31]
Farabegoli F, Vettraino M, Manerba M, Fiume L, Roberti M, Di Stefano G. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci 2012; 47(4): 729-38.
[http://dx.doi.org/10.1016/j.ejps.2012.08.012] [PMID: 22954722]
[32]
Zhai X, Yang Y, Wan J, Zhu R, Wu Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep 2013; 30(6): 2983-91.
[http://dx.doi.org/10.3892/or.2013.2735] [PMID: 24064966]
[33]
Vettraino M, Manerba M, Govoni M, Di Stefano G. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. Anticancer Drugs 2013; 24(8): 862-70.
[http://dx.doi.org/10.1097/CAD.0b013e328363ae50] [PMID: 23797802]
[34]
Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255(2): 179-87.
[http://dx.doi.org/10.1046/j.1365-2796.2003.01271.x] [PMID: 14746555]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2021
Published on: 15 February, 2021
Page: [171 - 181]
Pages: 11
DOI: 10.2174/2212796815666210216101221
Price: $25

Article Metrics

PDF: 226
HTML: 1